Anavex Life Sciences Corp... (AVXL)
| Bid | 8.75 |
| Market Cap | 761.32M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -46.49M |
| EPS (ttm) | -0.55 |
| PE Ratio (ttm) | -16.27 |
| Forward PE | 6.78 |
| Analyst | Buy |
| Ask | 9.09 |
| Volume | 347,300 |
| Avg. Volume (20D) | 1,106,067 |
| Open | 8.84 |
| Previous Close | 8.84 |
| Day's Range | 8.71 - 8.98 |
| 52-Week Range | 3.25 - 14.44 |
| Beta | 0.80 |
About AVXL
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinica...
Analyst Forecast
According to 3 analyst ratings, the average rating for AVXL stock is "Buy." The 12-month stock price forecast is $46, which is an increase of 413.97% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
Anavex: Looking At Different Statistical Approaches Before EMA OpinionAnavex Life Sciences Corp.'s stock surged over 50% due to EMA's acceptance of blarcamesine for Alzheimer's review, marking a pivotal moment for the company. Despite mixed trial results, blarcamesine s...
2 months ago · seekingalpha.com
Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for the treatment of patients with Alzheimer's Disease by year-end of 2025. The global market for Alzheim...
2 months ago · seekingalpha.com
Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call TranscriptAnavex Life Sciences Corp. (NASDAQ:AVXL ) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President & CEO Sandra Boenisch...
